Veradermics Doses First Patient With New Oral Hair Loss Drug

A fascinating new dermatology startup, Veradermics, announced today the dosing of its first patient in a phase 2 clinical trial for pattern hair loss. What makes this news especially exciting is that Veradermics’ drug, for now referred to as VDPHL, is an oral medication. Further, it’s a non-hormonal drug, which means it does not act on androgen hormones, such as DHT, like the drugs finasteride or dutasteride do. This means that users will likely not have to worry about sexual-related side effects. While information about VDPHL is limited at this time, Veradermics describes it as a “proprietary, non-hormonal oral treatment being developed for pattern hair loss.” Stay tuned for further information about this drug program here on Follicle Thought.